Find a Clinical Trial by Adult Cancer Type

Adult Cancers
Childhood Cancers
Doctor
Drug
Phase

Back to Adult Cancers

Cancer Type: Melanoma

34 protocol(s) meet the specified criteria. Please click on the protocol number to get more information about the trial.

Show: Only Melanoma specific trials All trials that include Melanoma

Doctor	Protocol No.	Title
Asher, Arash	IIT2019-07-ASHER-QIGONG	IIT2019-07-ASHER-QIGONG: A Mind-Body Intervention for Chemotherapy-Induced Peripheral Neuropathy (IRB#56)
Balmanoukian, Ani	AB154CSP0001	AB154CSP0001: A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants with Advanced Malignancies (IRB#57210)
Balmanoukian, Ani	204691	204691: A Phase I Open Label study of GSK3359609 administered alone and in combination with anticancer agents in subjects with selected advanced solid tumors (IRB:54166)
Balmanoukian, Ani	M16-438	M16-438: A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands (IRB#49976)
Balmanoukian, Ani	M15-862	M15-862: A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects with Advanced Solid Tumors (IRB#46931)
Balmanoukian, Ani	INCMGA0012-102	A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors (IRB#53849)
Boasberg, Peter D	4020-01-001	4020-01-001: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (IRB#49142)
Faries, Mark	MRNA-4157-P201	MRNA-4157-P201: A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (IRB#57650)
Faries, Mark	716-01	716-01: Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716) (IRB#53866)
Freedland, Stephen	IIT2018-19-GRESH-DIGISTEP	Digitally-captured Step counts for Evaluating Performance Status in Advanced Cancer Patients: A single cohort, prospective trial (Digi-STEPS) (IRB#55271)
Gayther, Simon	1080	The Gilda Radner Hereditary Cancer Program (IRB#1080)
Gutierrez, Rodolfo	R2810-ONC-1788	R2810-ONC-1788: A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy In Patients with High Risk Cutaneous Squamous Cell Carcinoma (IRB#57958)
Gutierrez, Rodolfo	AB928CSP0005	A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies (IRB#55460)
Hamid, Omid	CTMX-M-072-002	A Phase Ib, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of IN10018 as Monotherapy and Combination Therapy in Subjects with Metastatic Melanoma(IRB#STUDY0000037)
Hamid, Omid	D8510C00001	D8510C00001: A Phase 1, Open-label, Dose-escalation and Expansion Study of MEDI1191 Administered Intratumorally as Monotherapy and in Combination with Durvalumab in Subjects with Advanced Solid Tumors (IRB#57295)
Hamid, Omid	PICI0014	A Multicenter Phase 1b Randomized, Placebo-controlled, Blinded Study to Evaluate the Safety, Tolerability and Efficacy of Microbiome Study Intervention Administration in Combination with Anti-PD-1 Therapy in Adult Patients with Unresectable or Metastatic Melanoma (IRB#55774)
Hamid, Omid	NC318-01	NC318-01: A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects with Advanced or Metastatic Solid Tumors (IRB#54833)
Hamid, Omid	587-00	587-00: A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial. (IRB#54410)
Hamid, Omid	MK-7902-003	MK-7902-003: A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants with Advanced Melanoma(LEAP-003) (IRB#56450)
Hamid, Omid	ARRAY-818-201	ARRAY-818-201: A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis (IRB# 56598)
Hamid, Omid	CMIW815X2102J	CMIW815X2102J: A Phase Ib, open label, multicenter study of the safety and efficacy of MIW815 (ADU-S100) administered by intratumoral injection with PDR001 to patients with advanced/metastatic solid tumors or lymphomas (IRB#49591)
Hamid, Omid	INCAGN2390-101	INCAGN2390-101: A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies (IRB#54179)
Hamid, Omid	CPDR001J2201	A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (IRB#53431)
Hamid, Omid	CTMX-M-072-001	An open-label, dose-finding and proof of concept study of the PD-L1 probody therapeutic, CX-072, as monotherapy and in combination with yervoy (ipilimumab) or with zelboraf (vemurafenib) in subjects with advanced or recurrent solid tumors or lymphomas (IRB#46401)
Hamid, Omid	R3767-ONC-1613	R3767-ONC-1613: A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies (IRB#48031)
Hamid, Omid	GO40558	GO40558: A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination with Pembrolizumab versus Pembrolizumab in Patients with Previously Untreated Advanced Melanoma (IRB#54796)
Hamid, Omid	TAPUR	Targeted Agent and Profiling Utilization Registry (TAPUR) Study (IRB#49119)
Hendifar, Andrew	MK-7339-002	MK7339-002: A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (IRB#57241)
Labadzhyan, Artak	IIT2016-09-LABADZHYAN-ICI	IIT2016-09-LABADZHYAN-ICI: Prospective study of predictive markers and changes in specific endocrine hormones in patients with metastatic cancers treated with immune checkpoint inhibitors. (IRB#45026)
Mita, Monica	RGX-104-001	A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies (IRB#46271)
Mita, Alain	XMAB20717-01	XmAb20717-01: A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects with Selected Advanced Solid Tumors (IRB #53244)
Mita, Monica	1381-1	1381.1: An open-label, Phase I trial to determine the maximum-tolerated dose and investigate safety, pharmacokinetics, and efficacy of BI 754091 in patients with advanced solid tumors (IRB#053757)
Natale, Ronald	IIT2017-11-NATALE-LUNG01	IIT2017-11-NATALE-LUNG01: Biomarkers of Targeted Therapy-Induced Apoptosis and Mechanisms of Sensitivity/Resistance in Patients with Advanced Cancers (IRB#53113)
Shiao, Stephen	IIT2015-07-SHIAO-HIFIDELI	Novel High Fidelity Functional Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis (IRB#43055)

New studies open frequently, please check back for updates

The following physicians have trials which are currently recruiting patients. If you do not see the doctor you are searching for, please call 310-423-2133 for more information.

Phase I

Researchers test an experimental drug or treatment in a small group of people (20-80), to evaluate its safety and identify side effects. Often these trials are not disease specific and may include more than one type of cancer.

Phase II

The experimental drug or treatment is administered to a larger group of people (100-300) to determine its effectiveness and to further evaluate its safety.

Phase III

The experimental drug or treatment is administered to larger groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it with standard or equivalent treatment, and collect information that will allow the experimental drug or treatment to be used safely.